Labcorp Holdings INC Form 4 insider transactions

Adam H Schechter, President & CEO and a Director of Labcorp Holdings Inc., sold 4,669 shares of common stock on August 11, 2026 for $320.37 per share.

Amy B. Summy, EVP, Chief Marketing Officer of Labcorp Holdings Inc., sold 924 shares of common stock on August 4, 2026 for $306.74 per share.

Peter J Wilkinson, SVP, Chief Accounting Officer of Labcorp Holdings Inc., sold 1,420 shares of common stock on August 3, 2026.

Labcorp Holdings Inc. executive Kathryn W. Kyle reports transactions involving restricted stock units and common stock, including a sale under a 10b5-1 plan.

Bryan T. Vaughn, EVP and President of Diagnostics at Labcorp Holdings Inc., reported transactions involving restricted stock units and common stock.

Labcorp Holdings Inc. reports a Form 4 filing detailing the sale of common stock by EVP, Chief Legal Officer Kathryn W. Kyle.

Labcorp Holdings Inc. reports that President & CEO Adam H. Schechter sold 5,903 shares of common stock on May 11, 2026, as part of a pre-arranged 10b5-1 trading plan.

CEO Adam H. Schechter received 58,470 Labcorp shares from a 2023 performance award and withheld 26,106 shares for taxes, bringing direct holdings to 113,137.

EVP and CHRO Anita Z. Graham acquired 6,604 Labcorp shares from a vested performance award and had 2,879 shares withheld for taxes, leaving 5,185 shares owned.

Labcorp EVP and Diagnostics President Mark S. Schroeder reported net share acquisitions from 2023 performance awards on March 26, 2026, with tax withholdings at $268.38 per share.

Labcorp executive Brian J. Caveney received 11,290 shares from vested performance awards and withheld 4,905 shares for taxes, ending with 36,491.9234 shares owned directly.

Labcorp SVP/Chief Accounting Officer Peter J. Wilkinson received 2,388 shares from a performance award, withheld 755 for taxes, and sold 1,633 under a Rule 10b5-1 plan, ending with 1,852 shares.

On March 26, 2026, Labcorp EVP Bryan T. Vaughn received 1,584 shares from a 2023 performance award and had 451 shares withheld for taxes, ending with 6,745.5702 shares owned directly.

Labcorp’s EVP, Corporate Affairs reported a performance award vesting of 6,382 shares and tax withholding of 2,722 shares at $268.38, leaving 6,238.9467 shares held directly.

Labcorp EVP and CMO Amy B. Summy received 3,994 shares from a 2023 performance award and withheld 1,836 shares for taxes, lifting her direct holdings to 7,879.5 shares.

Labcorp EVP/CIO/CTO Akinbolade Oyegunwa received 1,340 shares from a 2023 performance award and netted 958 shares after tax withholding.

Labcorp EVP Jonathan C. Meltzer received 2,388 performance shares, withheld 711 shares for taxes, and sold 839 shares under a Rule 10b5-1 plan, ending with 3,620.3256 shares owned.

Labcorp’s EVP and Chief Legal Officer, Kathryn W. Kyle, acquired 1,584 shares from a vested performance award and had 451 shares withheld for taxes, resulting in a net increase of 1,133 shares.

Megan D. Bailey acquired 1,184 shares from a vested performance award; 481 shares were withheld for taxes at $268.38, increasing her direct holdings to 4,851.

Labcorp's President & CEO, Adam H. Schechter, sold 8,705 shares of common stock for approximately $2.44 million under a pre-arranged trading plan.

Labcorp's EVP of Corporate Affairs, Sandra D. van der Vaart, sold 547.5397 shares of common stock for $284.91 per share on February 27, 2026, under a Rule 10b5-1 plan.

Labcorp's EVP, Brian J. Caveney, sold 1,500 shares of common stock for $286.305 per share under a Rule 10b5-1 plan.

Labcorp's SVP, Chief Accounting Officer, Peter J. Wilkinson, sold 666 shares of common stock for $277.94 per share under a pre-arranged 10b5-1 plan.

Labcorp's EVP and Chief Marketing Officer, Amy B. Summy, reported the vesting of 230 Restricted Stock Units and subsequent acquisition of common stock, alongside a tax-related disposition, effective February 11, 2026.

Labcorp's SVP and Chief Accounting Officer, Peter J. Wilkinson, reported common stock acquisitions and tax-related dispositions following the vesting of Restricted Stock Units.

Labcorp's Chief Financial Officer, Julia Aijun Wang, exercised 860 Restricted Stock Units and sold 245 shares to cover tax obligations.

Labcorp's EVP of Diagnostics, Bryan T. Vaughn, converted Restricted Stock Units into common stock and sold a portion to cover tax obligations.

Labcorp's EVP of Corporate Affairs, Sandra D. van der Vaart, reported the vesting and exercise of Restricted Stock Units and subsequent sale of shares to cover tax obligations.

Labcorp's EVP, President of Diagnostics and COO, Mark S. Schroeder, exercised 806 Restricted Stock Units and sold 259 shares to cover tax obligations.

Labcorp's President and CEO, Adam H. Schechter, reported a sale of common stock and the vesting and conversion of restricted stock units.